Commentary|Videos|August 13, 2024

Safety Considerations for Newly Approved IPX203

Name: IPX203 as treatment for PD
Uploaded: 2024-08-13T19:00:00Z
Duration: 4 minutes
Description: Safety considerations for newly approved IPX203

Author(s)Robert A. Hauser, MD, MBA, Hubert Fernandez, MD

The panelists discussed the safety profile of IPX203, considering challenges with transitioning, dosing strategies, and monitoring and adjusting patients’ individual dosage.

Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules, as a treatment for patients with Parkinson disease (PD). Marketed as Crexont, the therapy is an oral formulation CD/LD which includes immediate-release granules as well as extended-release pellets. In its announcement, Amneal noted it expects the oral treatment to be available to patients in the United States in September 2024.

Related to this article

September 28th, 2026

FDA Approves Tavapadon for the Treatment of Parkinson Disease

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

October 6th, 2026

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

October 6th, 2026

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

October 6th, 2026

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

October 5th, 2026

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

October 6th, 2026

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy

Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.

October 5th, 2026

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

October 5th, 2026

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.